Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696511 | 0.91 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL1696512 | 0.87 | MTNR1A (0.42) | MTNR1AMTNR1BPDE10A | |
| SCHEMBL1285571 | 0.87 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL1285176 | 0.87 | MTNR1A (0.53) | MTNR1AMTNR1B | |
| SCHEMBL3428772 | 0.87 | MTNR1A (0.43) | MTNR1AMTNR1B | |
| SCHEMBL1285050 | 0.86 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL1285845 | 0.84 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL1285121 | 0.84 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL1285591 | 0.83 | MTNR1A (0.48) | MTNR1AMTNR1B | |
| SCHEMBL1284713 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088809-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-12 | — | — | US | disclosed |
| EP-2266975-A1 | 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds | Ferrer Internacional, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088809-A1 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS | MTNR1A, MTNR1B, TPH2 | PIM1 2871/4885PIM3 2701/4885PIM2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.